Author:
Perkins Daniel,Ruffell Simon G. D.,Sarris Jerome
Abstract
Abstract
Ayahuasca is a psychedelic plant brew originating in the Amazon basin. It is typically made from two basic components: the ayahuasca vine (Banisteriopsis caapi), containing various harmala alkaloids, and the leaves of a plant containing the potent psychedelic dimethyltryptamine (DMT), such as the chacruna plant (Psychotria viridis). Evidence suggests the brew has been used for at least hundreds of years, primarily by indigenous tribes for a range of purposes including psychological and physical healing. The components of the brew exert a range of neurochemical effects, with recent research suggesting it may be effective in treating depression, anxiety, and addiction. The harmala alkaloids found in the vine are monoamine oxidase-A enzyme inhibitors (MAOIs). These compounds prevent the deamination of DMT as well as exerting their own psychotropic effects. DMT is known to modulate the signalling of serotonin and dopamine via serotonin and dopamine receptor agonism, as well as sigma-1 agonism. Interest in the plant brew has increased dramatically in recent years, with large numbers of ‘ayahuasca tourists’ visiting the Amazon basin to partake in ceremonies with the intention of treating a range of different conditions. Similarly, research into ayahuasca has increased, both in naturalistic and clinical settings, with potential medicalization giving rise to complex ethical issues that must be carefully considered.
Publisher
Oxford University PressOxford
Reference49 articles.
1. A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naive subjects.;Journal of Psychoactive Drugs,2009
2. Assessment of alcohol and tobacco use disorders among religious users of ayahuasca.;Frontiers in Psychiatry,2018
3. C6P34Barceloux DG (2012) Ayahuasca, harmala alkaloids, and dimethyltryptamines, in Robert B Palmer, ed., Toxicology associates. John Wiley & Sons, 768–780.
4. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans.;European Neuropsychopharmacology,2015